Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

What this Trial Is About

Systemic lupus erythematosus (SLE) is a condition that affects females much more often than males. This research aims to find out if a drug called Gonadotropin-releasing hormone agonist (GnRHa) can protect women's ovaries during treatment with cyclophosphamide (CYC), which is commonly used for severe SLE but may cause infertility by damaging ovaries. The study compares women receiving CYC with GnRHa to those receiving CYC alone and also includes a control group of women with SLE who have not received CYC. Participants fall into three groups: women receiving CYC alone, women receiving both CYC and GnRHa (leuprolide acetate injected monthly or every three months), and age-matched female SLE patients without reproductive disorders who have not received CYC. The study collects data through patient surveys and medical record reviews. The survey asks about menstrual cycles, pregnancy history, and infertility, and can be completed on paper, online, by phone, or in person. During the study, researchers review medical records for SLE disease activity, blood test results, prior treatments, and reproductive health history including fertility treatments and sexually transmitted infections. The main outcome measured is primary ovarian insufficiency (POI) at the end of the study. Secondary measures include the effects of treatment on menstrual cycles and disease activity scores. Participation involves a one-time 30-minute survey and medical records review, with data collected securely to assess ovarian function and the impact of GnRHa co-treatment during CYC therapy.

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires